8048-52-0
基本信息
吖啶黄
吖黄素
吖啶黃素
3,6-DIAMINO-10-METHYLACRIDINIUM CHLORIDE
ACRIFLAVINE
ACRIFLAVINE BASE
ACRIFLAVINE NEUTRAL
CI 46000
CI NO 46000
EUFLAVIN
EUFLAVINE
TRYPAFLAVINE
TRYPAFLAVINE FS
XANTHACRIDINE
2,8-diamino-10-methylacridiniumchloridemixturewith2,8-diaminoacridine
3,6-diamino-10-methylacridiniumchloridemixturewith3,6-acridinediamine
3,6-diaminoacridinemixturewith3,6-diamino-10-methylacridiniumchloride
acridinium,3,6-diamino-10-methyl-,chloridemixedwith3,6-acridinediamine
angiflan
assiflavine
bialflavina
bioacridin
物理化学性质
熔点 | 179-181 °C |
沸点 | 612.69°C (rough estimate) |
密度 | 1.0933 (rough estimate) |
折射率 | 1.6000 (estimate) |
储存条件 | -20°C储存 |
溶解度 | 在水中的溶解度为0.33g/mL(lit.)(lit.) |
形态 | 粉末 |
颜色 | 深橙色至棕红色 |
水溶解性 | H2O: 0.33g/mL (lit.)(lit.) |
Merck | 123 |
CAS 数据库 | 8048-52-0(CAS DataBase Reference) |
EPA化学物质信息 | Xanthacridinum (8048-52-0) |
安全数据
危险性符号(GHS) | GHS07 |
警示词 | 警告 |
危险性描述 | H302-H315-H319-H335 |
防范说明 | P261-P264-P270-P301+P312-P302+P352-P305+P351+P338 |
危险品标志 | Xn,N |
危险类别码 | R22-R37/38-R41-R50/53 |
安全说明 | S26-S39-S60-S61 |
危险品运输编号 | UN 3077 9/PG 3 |
WGK Germany | 3 |
RTECS号 | AR9660000 |
海关编码 | 29339900 |
应用领域
知名试剂公司产品信息
Acriflavine neutral, 13.3-15.8% chlorine(8048-52-0) Acros Organics
吖啶黄价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/11/11 | XW80485202 | 吖啶黄素 acriflavine;3,6-diamino-10-methylacridinium chloride mixture with 3,6-diaminoacridine(proflavine);euflavine | 8048-52-0 | 25G | 483元 |
2024/11/11 | XW80485201 | 吖啶黄素 acriflavine;3,6-diamino-10-methylacridinium chloride mixture with 3,6-diaminoacridine(proflavine);euflavine | 8048-52-0 | 5G | 114元 |
2024/11/08 | 21140 | 吖啶黄 Acriflavine neutral, 13.3-15.8% chlorine, Thermo Scientific Chemicals | 8048-52-0 | 25g | 726元 |
常见问题列表
Acriflavine is identified as a potent inhibitor of the MCT4 that can inhibit the binding between Basigin and MCT4. Acriflavine significantly inhibits growth and self-renewal potential of several glioblastoma neurosphere lines. The HIF-1 inhibitor acriflavine decreases survival and growth of CML cells. It targets stem cell potential of CML cells.
Acriflavine treatment inhibits intratumoral expression of VEGF and tumor vascularization. In a murine CML model, acriflavine decreases leukemia development and reduces LSC maintenance. Acriflavine retards tumor growth in a murine model of breast cancer. The combination of sunitinib with acriflavine significantly decreases vascular endothelial growth factor and TGF-β expression and reduces tumor vasculature followed by increased intratumor necrosis and apoptosis.